01.29.21
Like many companies, the effects of the COVID-19 pandemic were clearly felt by Schott in parts of the portfolio. However, its pharmaceutical business did very well, driving overall growth in 2020.
“We stayed on course even in these difficult economic times. Therefore, we are quite satisfied with the past fiscal year,” said Dr. Frank Heinricht, chairman of the Board of Management. “This is largely thanks to the groundwork we have done in recent years. We have invested consistently, introduced many innovations to the market and have demonstrated stringent portfolio management.”
Sales rose by 2.2% to €2.24 billion. Operating profit (EBIT) also improved, and now stands at €288 million. The number of employees rose to around 16,500, 5,900 of whom are based in Germany.
Even before COVID-19, SCHOTT invested approximately €320 million or an increase of around 24%, including a new building for pharmaceutical packaging in Müllheim in the German state of Baden, a new plant in China and new melting units in India, both for pharmaceutical tubing production.
The Fight Against COVID-19
SCHOTT currently produces more than 11 billion pharmaceutical packages for vaccines and liquid medications every year. Three out of four projects worldwide that either already manufacture or are still researching a COVID-19 vaccine use glass vials from SCHOTT.
The company will have delivered enough vials for two billion vaccine doses by the end of 2021. SCHOTT has already been investing in its production capacity since the spring of 2019 and was therefore able to ramp up capacities quickly during the pandemic. To achieve a further boost, SCHOTT will once again increase last year’s record investments by spending €350 million.
“We stayed on course even in these difficult economic times. Therefore, we are quite satisfied with the past fiscal year,” said Dr. Frank Heinricht, chairman of the Board of Management. “This is largely thanks to the groundwork we have done in recent years. We have invested consistently, introduced many innovations to the market and have demonstrated stringent portfolio management.”
Sales rose by 2.2% to €2.24 billion. Operating profit (EBIT) also improved, and now stands at €288 million. The number of employees rose to around 16,500, 5,900 of whom are based in Germany.
Even before COVID-19, SCHOTT invested approximately €320 million or an increase of around 24%, including a new building for pharmaceutical packaging in Müllheim in the German state of Baden, a new plant in China and new melting units in India, both for pharmaceutical tubing production.
The Fight Against COVID-19
SCHOTT currently produces more than 11 billion pharmaceutical packages for vaccines and liquid medications every year. Three out of four projects worldwide that either already manufacture or are still researching a COVID-19 vaccine use glass vials from SCHOTT.
The company will have delivered enough vials for two billion vaccine doses by the end of 2021. SCHOTT has already been investing in its production capacity since the spring of 2019 and was therefore able to ramp up capacities quickly during the pandemic. To achieve a further boost, SCHOTT will once again increase last year’s record investments by spending €350 million.
